GlassScriptPhysician profile
Michael T Asbach
NPI 1699030411
$961,872.85
in general payments reported to CMS, 2019-2025
57 companies · $296K in 2025
The $296K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97K · 2022: $148K · 2023: $195K · 2024: $226K · 2025: $296K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $404K · Consulting Fee: $148K · Honoraria: $66K · Travel and Lodging: $65K · Food and Beverage: $33K · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $404,286.00 |
| Consulting Fee | $148,288.50 |
| Honoraria | $66,238.00 |
| Travel and Lodging | $64,835.44 |
| Food and Beverage | $33,122.64 |
| Education | $260.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $272,762.27 | 2021-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $249,785.45 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $125,603.01 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99,460.72 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $78,742.69 | 2024-2025 | Cobenfy, Sotyktu |
| Teva Pharmaceuticals USA, INC. | $37,496.81 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $33,841.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $28,363.89 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Avanir Pharmaceuticals, INC. | $9,881.20 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $8,365.65 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Biogen, INC. | $3,026.55 | 2021-2025 | Zurzuvae, Skyclarys |
| Sage Therapeutics, LLC | $2,289.50 | 2023-2024 | |
| Allergan, INC. | $1,950.00 | 2021 | |
| Alkermes, INC. | $1,762.44 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $1,684.64 | 2021-2025 | Rexulti, Brintellix |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,376.45 | 2021-2025 | Fanapt, Hetlioz, Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $913.71 | 2021-2025 | Trintellix, Hyqvia |
| Sunovion Pharmaceuticals INC. | $881.43 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $519.08 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $430.74 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $334.97 | 2021-2024 | Qelbree |
| Acadia Pharmaceuticals INC | $278.84 | 2021-2022 | |
| Indivior INC. | $246.19 | 2021-2025 | Sublocade |
| Eisai INC. | $242.93 | 2021-2022 | |
| Livanova USA, INC. | $165.74 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator, Vns Therapy Sentiva Model 1000 Generator |
| Corium, LLC | $164.32 | 2023-2025 | Azstarys, Adlarity |
| Arbor Pharmaceuticals, INC. | $153.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $143.89 | 2021 | |
| Orexo US, INC. | $95.25 | 2021-2024 | Zubsolv |
| Catalyst Pharmaceuticals, INC. | $94.67 | 2022-2025 | |
| Bausch Health US, LLC | $80.68 | 2021-2025 | Wellbutrin |
| Azurity Pharmaceuticals, INC. | $72.93 | 2023-2024 | Horizant, Horizant |
| Ucb, INC. | $67.53 | 2023-2024 | Rystiggo |
| Merck Sharp & Dohme LLC | $60.24 | 2022 | |
| Merz Pharmaceuticals, LLC | $59.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.85 | 2025 | |
| Abbott Laboratories | $36.61 | 2021-2022 | |
| Noven Therapeutics, LLC | $36.51 | 2024 | Secuado, Xelstrym |
| Harmony Biosciences LLC | $34.65 | 2023 | Wakix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.75 | 2024 | Rejoyn |
| Biohaven Pharmaceutical Holding Company LTD. | $28.28 | 2022 | |
| Currax Pharmaceuticals LLC | $25.24 | 2021-2022 | |
| Lilly USA, LLC | $23.91 | 2023 | Reyvow, Emgality |
| Invivyd INC | $23.15 | 2025 | Pemgarda |
| Upsher-Smith Laboratories LLC | $18.54 | 2021 | |
| Sk Life Science, INC. | $18.08 | 2022 | |
| Amgen INC. | $18.01 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.91 | 2025 | Onpattro |
| Alfasigma USA, INC. | $16.31 | 2021 | |
| Celgene Corporation | $15.86 | 2025 | Zeposia |
| Fennec Pharmaceuticals, INC. | $15.77 | 2023 | Pedmark |
| Luye Pharma (USA) LTD. | $14.18 | 2025 | Erzofri Extended-Release |
| Banner Life Sciences, LLC | $13.71 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.86 | 2023 | Rytary |
| Almatica Pharma LLC | $12.63 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.53 | 2022 | |
| Janssen Biotech, INC. | $10.44 | 2024 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Asbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.